证券代码：000908 证券简称：*ST景峰 公告编号：2025-088 湖南景峰医药股份有限公司 关于公司召开第一次债权人会议的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 重要内容提示： 湖南景峰医药股份有限公司（以下简称"景峰医药"或者"公司"）于 2025 年 10 月 21 日收到湖南省常德市中级人民法院（以下简称"常德中院"或者"法院"） 送达的（2024）湘 07 破申 7 号《民事裁定书》和（2025）湘 07 破 15 号《决定书》， 裁定受理彭东钜、上海鑫绰投资管理有限公司（以下统称"申请人"）对公司的重 整申请，并指定北京市中伦律师事务所担任公司管理人。详见公司于 2025 年 10 月 22 日披露的《关于法院裁定受理公司重整并指定管理人及公司股票交易将被实施退 市风险警示暨公司股票停复牌并变更证券简称的公告》（公告编号：2025-075）。 2025 年 10 月 22 日 ， 常 德 中 院 在 全 国 企 业 破 产 重 整 案 件 信 息 网 （ https://pccz.court.gov.cn/pcajxxw/ ...

Meeting Overview - The second extraordinary general meeting of shareholders was held on November 19, 2025, with both on-site and online voting options available [3][4] - A total of 1,052 shareholders attended, representing 210,541,180 shares, which accounts for 23.9313% of the total voting shares [4] Voting Results - The proposal to reappoint the accounting firm received 99.2387% approval from the attending shareholders, with 208,938,280 shares in favor [8] - The proposal to elect a non-independent director was approved with 99.4873% support, totaling 209,461,780 shares [11] Legal Compliance - The meeting was witnessed by lawyers from Guangdong Chongli Law Firm, confirming that the procedures and resolutions complied with relevant laws and regulations [13]

证券代码：000908 证券简称：*ST景峰 公告编号：2025-087 湖南景峰医药股份有限公司 2025 年第二次临时股东大会决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 特别提示： 1、本次股东大会没有出现否决议案、增加或减少议案的情形。 2、本次股东大会没有涉及变更以往股东大会决议。 一、会议召开和出席情况 1、召开时间： 现场会议召开时间：2025 年 11 月 19 日 14:50； 网络投票时间：通过深圳证券交易所交易系统进行网络投票的时间为 2025 年 11 月 19 日 9:15-9:25，9:30-11:30 和 13:00-15:00；通过互联网投票系统投 票的时间为 2025 年 11 月 19 日 9:15-15:00。 2、召开地点：湖南省常德经济技术开发区樟木桥街道双岗社区桃林路 661 号双创大厦 18 楼湖南景峰医药股份有限公司会议室 3、召开方式：现场投票和网络投票相结合的方式 4、召集人：公司董事会 5、主持人：代理董事长张莉女士 6、会议的召开符合《公司法》等有关法律、行政法规、部门规章和《公司 章程》的规定 ...

关于 湖南景峰医药股份有限公司 2025 年第二次临时股东大会的 法律意见书 $$\Xi{\bf O}\,{\bf\Xi}\,{\bf\Xi}\,{\bf\rlap{\bf\Xi}}\,{\bf\rlap{\bf\Xi}}\,{\bf\rlap{\bf\Xi}}\,{\bf\rlap{\bf\Xi}}$$ 法律意见书 深圳市雅星路 8 号星河双子塔东塔 27 层 邮政编码：518100 27/F, East Tower, Galaxy Twin Towers, No. 8 Yaxing Road, Shenzhen 电话/Tel：0755-8958 5892 传真/Fax：0755-8958 6631 www.chonglilaw.com 广东崇立律师事务所 广东崇立律师事务所 关于湖南景峰医药股份有限公司 2025 年第二次临时股东大会的 法律意见书 （2025）崇立法意第 051 号 致：湖南景峰医药股份有限公司 广东崇立律师事务所（以下简称"本所"）接受湖南景峰医药股份有限公 司（以下简称"公司"）的委托，指派本所律师出席公司 2025 年第二次临时股 东大会（以下简称"本次股东大会"）进行法律见证，并 ...

New Stock Issuance - Hai'an Group (Stock Code: 001233) issued at a price of 48.00 on November 14, 2025[1] - Hangzhou Qilun B (Stock Code: 200771) has a cash option declaration period from November 19 to November 25, 2025[1] - Hailianxun (Stock Code: 300277) has a buyback request declaration period from November 12 to November 18, 2025[1] Market Alerts - Pingming Technology (Stock Code: 688109) reported severe abnormal fluctuations on November 13, 2025[1] - ST Yuancheng (Stock Code: 603388) and ST Zhongzhu (Stock Code: 600568) also reported abnormal fluctuations on November 11, 2025[1] - ST Green Kang (Stock Code: 002868) and Dongbai Group (Stock Code: 600693) reported abnormal fluctuations on November 14, 2025[1] Additional Information - Multiple companies including ST Meigu (Stock Code: 000615) and ST Xiangyu (Stock Code: 600107) have ongoing announcements related to stock performance and market conditions[1][2] - The report includes links to detailed announcements for each stock, providing transparency and access to further information for investors[1]

湖南景峰医药股份有限公司 股票交易异常波动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别风险提示： 1、湖南景峰医药股份有限公司（以下简称"公司"）于 2025 年 10 月 21 日收到湖南省常德市中级人民法院（以下简称"常德中院"）送达的（2024） 湘 07 破申 7 号《民事裁定书》和（2025）湘 07 破 15 号《决定书》，裁定受 理彭东钜、上海鑫绰投资管理有限公司对公司的重整申请，并指定北京市中伦 律师事务所担任公司管理人。 2、常德中院已裁定公司进入重整程序，公司可能存在因重整失败而被宣 告破产的风险。如果法院裁定公司破产，公司将被实施破产清算，根据《深圳 证券交易所股票上市规则》（以下简称《股票上市规则》）第 9.4.18 条第 （八）项的规定，公司股票将面临被终止上市的风险。 3、公司最近三个会计年度扣除非经常性损益前后净利润孰低者均为负值， 同时，大信会计师事务所（特殊普通合伙）（以下简称"大信"）对公司 2024 年度财务报告出具了带持续经营相关重大不确定性段落的无保留意见的审计报 告。截至本公告披露日，《2024 年年 ...

Group 1 - The flu season in China is expected to peak earlier this year, potentially in late December to early January, due to rising flu activity in southern provinces and different circulating strains compared to last year [4][5]. - The dominant strain this year is expected to be H3N2, which may lead to lower immunity in the population compared to last year's H1N1 strain [5]. - The demand for antiviral medications is anticipated to surge as the flu peak approaches, with several pharmaceutical companies ramping up production [8]. Group 2 - A-share flu-related stocks have shown strong performance, with notable increases in companies such as Weikang Pharmaceutical (+12.08%), Te Yi Pharmaceutical (+10.00%), and Renmin Tongtai (+9.97%) [2][3]. - The flu vaccine and antiviral drug sectors are expected to benefit from the anticipated increase in flu cases, highlighting a dual opportunity for investors in both short-term pandemic catalysts and long-term innovation [8]. - The overall flu-related industry, including vaccine development, infection control, and antiviral drugs, is likely to see a demand surge and value reassessment during the flu season [8].

Core Points - Liu Ting, an independent director of Hunan Jingfeng Pharmaceutical Co., Ltd., has submitted his resignation due to personal reasons [1] - His resignation will result in the independent directors' proportion on the board falling below one-third, and it will take effect after the election of a new independent director at the shareholders' meeting [1] - The board expresses gratitude for Liu Ting's contributions during his tenure [3] Summary by Sections - **Resignation Announcement** - Liu Ting has resigned from his position as an independent director and as the chairman of the remuneration and assessment committee, as well as a member of the nomination committee [1] - His term was originally set to last until the next board election [1] - **Impact on Board Composition** - The resignation will lead to a decrease in the proportion of independent directors on the board, necessitating a prompt election of a new independent director [1] - **Acknowledgment of Contributions** - The board has expressed sincere gratitude for Liu Ting's contributions during his time as an independent director [3]

Core Points - *ST Jingfeng (000908.SZ) announced the resignation of independent director Liu Ting due to personal reasons [1] - Liu Ting will no longer hold any positions within the company after his resignation [1] Company Summary - The board of directors received a written resignation report from independent director Liu Ting [1] - Liu Ting served as the chairman of the remuneration and assessment committee and a member of the nomination committee prior to his resignation [1]

证券代码：000908 证券简称：*ST 景峰 公告编号：2025-085 湖南景峰医药股份有限公司 关于公司独立董事辞职的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 湖南景峰医药股份有限公司（以下简称"公司"）董事会于近日收到独立 董事刘亭先生的书面辞职报告。刘亭先生因个人原因申请辞去公司独立董事及 董事会薪酬与考核委员会主任委员、提名委员会委员职务，辞职后将不再担任 公司任何职务。 刘亭先生原定任期至第八届董事会换届之日止。根据《中华人民共和国公 司法》《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范 运作》《公司章程》等相关规定，刘亭先生的辞职将导致公司独立董事占董事 会成员的比例低于三分之一，刘亭先生的辞职申请将在公司股东大会选举产生 新的独立董事后生效。在此期间，刘亭先生仍将按照相关法律、法规和《公司 章程》的规定继续履行其作为公司独立董事及董事会薪酬与考核委员会主任委 员、提名委员会委员职务。公司董事会将按照相关规定，尽快完成独立董事补 选工作。 截至本公告披露日，刘亭先生未持有公司股份，不存在应当履行而未履行 的承诺事 ...